A Value | B Growth | D Momentum | A VGM
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 23.68% |
| 2 | Buy | 17.55% |
| 3 | Hold | 9.21% |
| 4 | Sell | 4.93% |
| 5 | Strong Sell | 2.36% |
| S&P | 500 | 10.96% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
() Quote Overview » More Research » () Full Company Report
Company Summary
Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.
General Information
Jazz Pharmaceuticals PLC
FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD
DUBLIN, L2 D04 E5W7
Phone: 011-353-1634-7800
Fax: 353-1634-7850
Web: http://www.jazzpharma.com
Email: investorinfo@jazzpharma.com
| Industry | Medical - Drugs |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 6/30/2024 |
| Next EPS Date | 11/13/2024 |
EPS Information
| Current Quarter EPS Consensus Estimate | 5.49 |
| Current Year EPS Consensus Estimate | 19.53 |
| Estimated Long-Term EPS Growth Rate | 5.00 |
| Next EPS Report Date | 11/13/2024 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 111.29 |
| 52 Week High | 137.39 |
| 52 Week Low | 99.06 |
| Beta | 0.57 |
| 20 Day Moving Average | 753,439.12 |
| Target Price Consensus | 175.50 |
| 4 Week | -2.85 |
| 12 Week | 3.91 |
| YTD | -9.52 |
| 4 Week | -5.28 |
| 12 Week | -0.28 |
| YTD | -24.38 |
| Shares Outstanding (millions) | 61.75 |
| Market Capitalization (millions) | 6,872.55 |
| Short Ratio | NA |
| Last Split Date | NA |
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | 0.00 |
| Change in Payout Ratio | 0.00 |
| Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
| P/E (F1) | 5.70 |
| Trailing 12 Months | 6.24 |
| PEG Ratio | 1.14 |
| vs. Previous Year | 21.93% |
| vs. Previous Quarter | 135.86% |
| vs. Previous Year | 6.95% |
| vs. Previous Quarter | 13.51% |
| Price/Book | 1.83 |
| Price/Cash Flow | 4.00 |
| Price / Sales | 1.76 |
| 6/30/24 | 28.65 |
| 3/31/24 | 27.86 |
| 12/31/23 | 31.27 |
| 6/30/24 | 9.29 |
| 3/31/24 | 8.91 |
| 12/31/23 | 9.81 |
| 6/30/24 | 2.37 |
| 3/31/24 | 2.27 |
| 12/31/23 | 2.24 |
| 6/30/24 | 2.02 |
| 3/31/24 | 1.90 |
| 12/31/23 | 1.85 |
| 6/30/24 | 26.90 |
| 3/31/24 | 26.19 |
| 12/31/23 | 28.72 |
| 6/30/24 | 10.10 |
| 3/31/24 | 8.61 |
| 12/31/23 | 10.82 |
| 6/30/24 | 7.61 |
| 3/31/24 | 6.28 |
| 12/31/23 | 7.77 |
| 6/30/24 | 60.93 |
| 3/31/24 | 58.64 |
| 12/31/23 | 59.36 |
| 6/30/24 | 0.71 |
| 3/31/24 | 0.66 |
| 12/31/23 | 0.69 |
| 6/30/24 | 1.36 |
| 3/31/24 | 1.38 |
| 12/31/23 | 1.37 |
| 6/30/24 | 57.55 |
| 3/31/24 | 58.00 |
| 12/31/23 | 57.75 |